Metastatik Küçük Hücreli Dışı Akciğer Kanserinde NGS’e Göre Tedavi Yaklaşımları

Authors

Onur Ağcabay
https://orcid.org/0000-0002-5057-0218

References

Sung H, Filho AM, Laversanne M, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: A Cancer Journal for Clinicians. 2026;76(4): e70090.

Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung can- cer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Onco- logy. 2023;34(4): 339–357. doi:10.1016/j.annonc.2022.12.009

Puri S, Leighl NB, Ismaila N, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, 2026.3.0. Journal of Clinical Oncology. 2026;44(7): e15– e55.

Riely GJ, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 4.2026, NCCN Cli- nical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2026;24(4): e260017.

Riely GJ, Wood DE, Ettinger DS, et al. Non-small cell lung cancer, version 4.2024, NCCN Cli- nical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2024;22(4): 249–274. doi:10.6004/jnccn.2204.0023

Reuss JE, Zaemes J, Gandhi N, et al. Comprehensive molecular profiling of squamous non- small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking. Lung Cancer. 2025;200: 108101.

Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-gene- ration sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2024;35(7): 588–606.

Owen D, Ben-Shachar R, Feliciano J, et al. Actionable structural variant detection via RNA-N- GS and DNA-NGS in patients with advanced non-small cell lung cancer. JAMA Network Open. 2024;7(11): e2442970.

Drilon A, Duruisseaux M, Han JY, et al. Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter registry. Journal of Clinical Oncology. 2021;39(25): 2791–2802.

Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2022;33(8): 750–768.

Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology. 2021;16(10): 1647–1662. doi:10.1016/j.jtho.2021.06.017

Swalduz A, Schiffler C, Curcio H, et al. LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer. Journal of Thoracic Oncology. 2025;20(4): 437–450.

Penault-Llorca F, Kerr KM, Garrido P, et al. Expert opinion on NSCLC small specimen bio- marker testing — Part 1: Tissue collection and management. Virchows Archiv. 2022;481(3): 335–350. doi:10.1007/s00428-022-03343-2

Penault-Llorca F, Kerr KM, Garrido P, et al. Expert opinion on NSCLC small specimen biomar- ker testing — Part 2: Analysis, reporting, and quality assessment. Virchows Archiv. 2022;481(3): 351–366. doi:10.1007/s00428-022-03344-1

Aggarwal C, Marmarelis ME, Hwang WT, et al. Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non-small-cell lung cancer. JCO Precision Oncology. 2023;7: e2300191. doi:10.1200/PO.23.00191

Smeltzer MP, King JC, Connolly C, et al. The 2024 International Association for the Study of Lung Cancer global survey on biomarker testing. Journal of Thoracic Oncology. 2025;20(12): 1801–1813.

Westphalen CB, Boscolo Bielo L, Aftimos P, et al. ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in cli- nical practice. Annals of Oncology. 2025;36(6): 614–625.

Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untre- ated, EGFR-mutated advanced NSCLC. New England Journal of Medicine. 2020;382(1): 41–50. doi:10.1056/NEJMoa1913662

Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. New England Journal of Medicine. 2023;389(21): 1935–1948. doi:10.1056/NEJMoa2306434

Jänne PA, Planchard D, Kobayashi K, et al. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. New England Journal of Medicine. 2026;394(1): 27–38. doi:10.1056/NEJMoa2510308

Jänne PA, Planchard D, Kobayashi K, et al. CNS efficacy of osimertinib with or without che- motherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2024;42(7): 808–820. doi:10.1200/JCO.23.02219

Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-muta- ted advanced NSCLC. New England Journal of Medicine. 2024;391(16): 1486–1498. doi:10.1056/ NEJMoa2403614

Yang JC, Lu S, Hayashi H, et al. Overall survival with amivantamab-lazertinib in EGFR-muta- ted advanced NSCLC. New England Journal of Medicine. 2025;393(17): 1681–1693.

Felip E, Cho BC, Gutiérrez V, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Annals of Oncology. 2024;35(9): 805–816. doi:10.1016/j. annonc.2024.05.541

Hayashi H, Cho BC, Spigel DR, et al. Long-term impact of first-line amivantamab plus lazer- tinib versus osimertinib on mechanisms of acquired resistance in MARIPOSA: a brief report. Journal of Thoracic Oncology. 2026;21(9): 103894.

Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Annals of Oncology. 2024;35(1): 77–90. doi:10.1016/j. annonc.2023.10.117

Fang W, Zhao Y, Luo Y, et al.; HARMONi-A Study Investigators. Ivonescimab plus chemot- herapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA. 2024;332(7): 561–570.

Fang W, Zhao Y, Luo Y, et al.; HARMONi-A Study Investigators. Bispecific antibody ivones- cimab added to chemotherapy in EGFR-variant non-small cell lung cancer: the HARMONi-A randomized clinical trial. JAMA. 2026;336(4): 306–314.

Fang W, Wu L, Meng X, et al. Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC. New England Journal of Medicine. 2026;394(1): 13–26.

Lu S, Wang J, Yang N, et al. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): in- terim analysis of a multicentre, open-label, phase 3 randomised controlled trial. The Lancet. 2026;407(10526): 375–387.

Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. New England Journal of Medicine. 2023;389(22): 2039–2051. doi:10.1056/NEJ- Moa2306441

Miura S, Tanaka H, Misumi T, et al. Pragmatic randomized study of afatinib versus chemot- herapy for patients with non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: ACHILLES/TORG1834. Journal of Clinical Oncology. 2025;43(18): 2049– 2058.

Chmielecki J, Gray JE, Cheng Y, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 2023;14(1): 1070. doi:10.1038/s41467-023-35961-y

Tomić K, Vranić S. A remarkable year for NSCLC: seven new FDA approvals in 2025 across molecular targets. Biomolecules and Biomedicine. 2026;26(6): 869–871.

Yang JC, Lee DH, Lee JS, et al. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, me- tastatic nonsquamous non-small cell lung cancer. Journal of Clinical Oncology. 2024;42(34): 4029–4039. doi:10.1200/JCO.23.02747

Yang JC, Wang M, Doucet L, et al. Phase II dose-randomized study of sunvozertinib in pla- tinum-pretreated non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations (WU-KONG1B). Journal of Clinical Oncology. 2025;43(29): 3198–3208.

Okuma Y, Kubota K, Shimokawa M, et al. First-line osimertinib for previously untreated pa- tients with NSCLC and uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial. JAMA Oncology. 2024;10(1): 43–51. doi:10.1001/jamaoncol.2023.5013

Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Annals of Oncology. 2020;31(8): 1056–1064. doi:10.1016/j.an- nonc.2020.04.478

Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-po- sitive lung cancer. New England Journal of Medicine. 2020;383(21): 2018–2029. doi:10.1056/ NEJMoa2027187

Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-po- sitive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. Journal of Clinical Oncology. 2024;42(29): 3400–3409. doi:10.1200/JCO.24.00581

Shaw AT, Solomon BJ, Felip E, et al. Lorlatinib versus crizotinib as first-line treatment for ad- vanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. Annals of Oncology. 2026;37(9): 1242–1252.

Bearz A, Martini JF, Jassem J, et al. Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced NSCLC in relation to EML4::ALK variant type and ALK with or wit- hout TP53 mutations. Journal of Thoracic Oncology. 2023;18(11): 1581–1593.

Felip E, Shaw AT, Bearz A, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Annals of Oncology. 2021;32(5): 620–630. doi:10.1016/j.annonc.2021.02.012

Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of re- sistance and management. Nature Reviews Clinical Oncology. 2022;19(8): 499–514. doi:10.1038/ s41571-022-00639-9

Drilon A, Chiu CH, Fan Y, et al. Long-term efficacy and safety of entrectinib in ROS1 fusi- on-positive NSCLC. JTO Clinical and Research Reports. 2022;3(6): 100332. doi:10.1016/j.jtoc- rr.2022.100332

Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. New England Journal of Medicine. 2024;390(2): 118–131. doi:10.1056/NEJMoa2302299

Pérol M, Li W, Pennell NA, et al. Taletrectinib in ROS1+ non-small cell lung cancer: TRUST.

Journal of Clinical Oncology. 2025;43(16): 1920–1929.

Lin JJ, Choudhury NJ, Yoda S, et al. Spectrum of mechanisms of resistance to crizotinib and lor- latinib in ROS1 fusion-positive lung cancer. Clinical Cancer Research. 2021;27(10): 2899–2909. doi:10.1158/1078-0432.CCR-21-0032

Lee S, Hu L. Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor appro- ved for the treatment of ROS1-positive non-small cell lung cancer. Medicinal Chemistry Resear- ch. 2026;35(9): 1543–1547.

Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembroli- zumab in RET fusion-positive NSCLC. New England Journal of Medicine. 2023;389(20): 1839– 1850. doi:10.1056/NEJMoa2309457

Besse B, Subbiah V, Curigliano G, et al. Final efficacy and safety data from the phase I/II AR- ROW study of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer. Journal of Clinical Oncology. 2026;44(13): 1190–1197.

Lin JJ, Liu SV, McCoach CE, et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Annals of Oncology. 2020;31(12): 1725–1733. doi:10.1016/j.annonc.2020.09.015

Drilon A, Tan DSW, Lassen UN, et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers. JCO Precision Oncology. 2022;6: e2100418. doi:10.1200/PO.21.00418

Cho BC, Chiu CH, Massarelli E, et al. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Lung Cancer. 2024;188: 107442. doi:10.1016/j.lung- can.2023.107442

Schram AM, Goto K, Kim DW, et al. Efficacy of zenocutuzumab in NRG1 fusion-positive can- cer. New England Journal of Medicine. 2025;392(6): 566–576. doi:10.1056/NEJMoa2405008

Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. New England Journal of Medicine. 2021;384(25): 2371–2381. doi:10.1056/NEJMoa2103695

de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial. The Lancet. 2023;401(10378): 733–746. doi:10.1016/S0140-6736(23)00221-0

Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation. New England Journal of Medicine. 2022;387(2): 120–131. doi:10.1056/ NEJMoa2204619

Barlesi F, Yao W, Duruisseaux M, et al. Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. The Lancet. 2025;406(10503): 615–626. doi:10.1016/S0140-6736(25)00866-9

Chour A, Denis J, Mascaux C, et al. Brief report: severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-programmed cell death (ligand)1 and sotorasib therapy in KRAS G12C-mutant lung cancer. Journal of Thoracic Oncology. 2023;18(10): 1408–1415. doi:10.1016/j.jtho.2023.05.013

Planchard D, Besse B, Groen HJM, et al. Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. Journal of Thoracic Oncology. 2022;17(1): 103–115. doi:10.1016/j.jtho.2021.08.011

Riely GJ, Smit EF, Ahn MJ, et al. Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF V600-mutant metastatic non-small-cell lung cancer. Journal of Clinical Oncology. 2023;41(21): 3700–3711. doi:10.1200/JCO.23.00774

Johnson ML, Smit EF, Felip E, et al. Updated overall survival analysis from the phase II PHA- ROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer. Journal of Clinical Oncology. 2025;43(35): 3706–3713. doi:10.1200/ JCO-25-02023

Negrao MV, Skoulidis F, Montesion M, et al. Oncogene-specific differences in tumor mutatio- nal burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung can- cer. Journal for ImmunoTherapy of Cancer. 2021;9(8): e002891. doi:10.1136/jitc-2021-002891

Wolf J, Hochmair M, Han JY, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. The Lancet Onco- logy. 2024;25(10): 1357–1370. doi:10.1016/S1470-2045(24)00441-8

Mazieres J, Paik PK, Garassino MC, et al. Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrando- mized clinical trial. JAMA Oncology. 2023;9(9): 1260–1266. doi:10.1001/jamaoncol.2023.1962

Camidge DR, Bar J, Horinouchi H, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. Journal of Clinical Oncology. 2024;42(25): 3000–3011. doi:10.1200/JCO.24.00720

Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. New England Journal of Medicine. 2022;386(3): 241–251. doi:10.1056/NEJMoa2112431

Heymach JV, Ruiter G, Ahn MJ, et al. Zongertinib in previously treated HER2-mutant non- small-cell lung cancer. New England Journal of Medicine. 2025;392(23): 2321–2333. doi:10.1056/ NEJMoa2503704

Le X, Kim TM, Loong HH, et al. Sevabertinib in advanced HER2-mutant non-small-cell lung cancer. New England Journal of Medicine. 2025;393(18): 1819–1832. doi:10.1056/NEJ- Moa2511065

Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. Journal of Clinical Oncology. 2023;41(31): 4852–4863. doi:10.1200/JCO.23.01361

Hendriks LE, Kerr KM, Menis J, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2023;34(4): 358–376. doi:10.1016/j.annonc.2022.12.013

Ricciuti B, Arbour KC, Lin JJ, et al. Diminished efficacy of programmed death-(ligand)1 inhibi- tion in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. Journal of Thoracic Oncology. 2022;17(3): 399–410. doi:10.1016/j.jtho.2021.10.013

Skoulidis F, Araujo HA, Do MT, et al. CTLA4 blockade abrogates KEAP1/STK11-related resis- tance to PD-(L)1 inhibitors. Nature. 2024;635(8038): 462–471. doi:10.1038/s41586-024-07943- 7

McCoach CE, Rolfo C, Drilon A, et al. Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIB- RETTO-001. Journal of Thoracic Oncology. 2022;17(6): 768–778. doi:10.1016/j.jtho.2022.02.004

Cangır AK, Yumuk PF, Dizbay Sak S, et al. Lung cancer in Turkey. Journal of Thoracic Oncology. 2022;17(10): 1158–1170. doi:10.1016/j.jtho.2022.06.001

Canaslan K, Eken E, Bilici M, et al. Bridging East and West: real-world clinicogenomic lands- cape of metastatic NSCLC in Türkiye. Genes. 2025;16(12): 1446. doi:10.3390/genes16121446

Published

November 16, 2026

License

License